COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry.

[en] In a cohort of severe asthma patients, a small number of COVID-19 cases was found; none resulted in death or a very severe disease course. Use of biologics for severe allergic or severe eosinophilic asthma was not associated with a higher risk of COVID-19. https://bit.ly/3ndZmyD

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Hanon, Shane

Brusselle, Guy

Deschampheleire, Maud

Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie

Michils, Alain

Peché, Rudi

Pilette, Charles

Rummens, Peter

Schuermans, Daniel

Simonis, Hélène

Vandenplas, Olivier

Schleich, Florence ; Université de Liège - ULiège > Département des sciences de la motricité > Département des sciences de la motricité

Language :

English

Title :

COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry.

Publication date :

2020

Journal title :

European Respiratory Journal

ISSN :

0903-1936

eISSN :

1399-3003

Publisher :

European Respiratory Society, United Kingdom

Volume :

Issue :

Pages :

2002857

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 19 February 2021

Statistics

Number of views

59 (1 by ULiège)

Number of downloads

38 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Beurnier A, Jutant EM, Jevnikar M, et al. Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. Eur Respir J 2020; 56: 2001875.
Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020; 369: m1985.
Chhiba KD, Patel GB, Vu THT, et al. Prevalence and characterization of asthma in hospitalized and non-hospitalized patients with COVID-19. J Allergy Clin Immunol 2020; 146: 307–314.
Maes T, Bracke K, Brusselle GG. Reply to: inhaled corticosteroids and COVID-19. Am J Respir Crit Care Med 2020; 202: 900–902.
Xia Z. Eosinopenia as an early diagnostic marker of COVID-19 at the time of the epidemic. EClinicalMedicine 2020; 23: 100398.
Lommatzsch M, Stoll P, Virchow JC. COVID-19 in a patient with severe asthma treated with omalizumab. Allergy 2020; 75: 2705–2708.
García-Moguel I, Díaz Campos R, Alonso Charterina S, et al. COVID-19, severe asthma, and biologics. Ann Allergy Asthma Immunol 2020; 125: 357–359.
Haberman R, Axelrad J, Chen A, et al. Covid-19 in immune-mediated inflammatory diseases – case series from New York. N Engl J Med 2020; 383: 85–88.
Morais-Almeida M, Aguiar R, Martin B, et al. COVID-19, asthma, and biologic therapies: what we need to know. World Allergy Organ J 2020; 13: 100126.
Vultaggio A, Agache I, Akdis CA, et al. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: an EAACI statement. Allergy 2020; 75: 2764–2774.
Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584: 430–436.
Schleich F, Brusselle G, Louis R, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med 2014; 108: 1723–1732.
Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373.
Tong JY, Wong A, Zhu D, et al. The prevalence of olfactory and gustatory dysfunction in COVID-19 patients: a systematic review and meta-analysis. Otolaryngol Head Neck Surg 2020; 163: 3–11.
Sciensano. www.sciensano.be/nl. Date last accessed: 18 Jul 2020. Date last updated: 18 Jul 2020.
Peters MC, Sajuthi S, Deford P, et al. COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. Am J Respir Crit Care Med 2020; 202: 83–90.